Mips Logo

Mips

Licenses patented helmet technology to reduce rotational impact injuries in sports and construction.

MIPS | ST

Overview

Corporate Details

ISIN(s):
SE0009216278 (+4 more)
LEI:
549300LZSA4S0L54VQ25
Country:
Sweden
Address:
Kemistvägen 1B, 183 79 TÄBY
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Mips is a developer of helmet-based safety technology focused on reducing head injuries. Its core product is the Mips® Safety System (Multi-Directional Impact Protection System), a patented Brain Protection System (BPS). Born from scientific research by a brain surgeon and a biomechanics scientist, the system incorporates a low-friction layer inside helmets. This layer is designed to move slightly upon an angled impact, helping to redirect harmful rotational motion away from the head and potentially reducing the risk of certain brain injuries. Mips licenses its technology to numerous helmet manufacturers for use in products across a wide range of markets, including cycling, snow sports, motorcycling, equestrian, and construction.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-22 07:30
Quarterly Report
Swedish 2.2 MB
2025-10-22 07:30
Quarterly Report
English 2.2 MB
2025-07-16 07:30
Earnings Release
Swedish 1.9 MB
2025-07-16 07:30
Earnings Release
English 1.9 MB
2025-05-07 11:45
AGM Information
Kommuniké från årsstämman i Mips AB (publ) den 7 maj 2025
Swedish 36.0 KB
2025-05-07 11:45
AGM Information
Press release from the Annual General Meeting in Mips AB (publ) on 7 May 2025
English 33.4 KB
2025-04-24 07:30
Quarterly Report
Swedish 1.2 MB
2025-04-24 07:30
Quarterly Report
English 1.2 MB
2025-03-20 17:20
Annual Report (ESEF)
Swedish 2.5 MB
2025-02-05 18:10
Earnings Release
Mips updates long-term financial target
English 39.4 KB
2025-02-05 18:10
Report Publication Announcement
Mips uppdaterar långsiktigt finansiellt mål
Swedish 39.3 KB
2025-02-05 18:10
Earnings Release
Swedish 3.0 MB
2025-02-05 18:10
Annual Report
English 3.0 MB
2024-10-24 07:30
Quarterly Report
Swedish 1.3 MB
2024-10-24 07:30
Interim / Quarterly Report
English 1.4 MB

Automate Your Workflow. Get a real-time feed of all Mips filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mips

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mips via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-10-25 Thomas Bräutigam Other Sell 4,500 2,430,000.00 SEK
2023-09-14 John Fredrik Kjellberg Other Sell 10,300 3,705,837.00 SEK
2023-03-03 Maria Hedengren Other Buy 200 98,254.00 SEK
2022-10-18 Thomas Bräutigam Other Buy 2,000 609,594.40 SEK
2022-10-17 Thomas Bräutigam Other Buy 3,000 907,927.80 SEK
2022-05-06 Thomas Bräutigam Other Buy 1,000 580,600.00 SEK
2022-05-05 Thomas Bräutigam Other Buy 2,000 1,253,200.00 SEK
2022-03-07 Jonas Rahmn Other Buy 107 75,301.25 SEK
2022-03-07 Jonas Rahmn Other Buy 94 66,317.00 SEK
2022-03-07 Jonas Rahmn Other Buy 90 63,495.00 SEK

Peer Companies

Terns Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing small-molecule drugs for oncology & metabolic diseases.
United States of America
TERN
Tevogen Bio Holdings Inc. Logo
Developing precision, off-the-shelf T cell therapies for cancer, infections, and neuro disorders.
United States of America
TVGN
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom
TCF
Theriva Biologics, Inc. Logo
Develops systemic oncolytic virus therapies to selectively destroy difficult-to-treat cancers.
United States of America
TOVX
Thirdeye Systems Ltd. Logo
Develops AI-driven thermal/visual perception solutions for defense, security & autonomous systems.
Israel
THES
TiumBio Co., Ltd. Logo
Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.
South Korea
321550
Tiziana Life Sciences Ltd Logo
Biotech firm developing immunotherapies for neurodegenerative diseases like MS and Alzheimer's.
United States of America
TLSA
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden
TOL
ToolGen Incorporated Logo
A biotech firm licensing genome editing patents for therapeutics and agriculture.
South Korea
199800
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.